Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ADMA Biologics's share price for the quarter that ended in Dec. 2023 was $4.52. ADMA Biologics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 226.1 Mil. Therefore, ADMA Biologics's market cap for the quarter that ended in Dec. 2023 was $1,021.8 Mil.
ADMA Biologics's quarterly market cap
declined
from Jun. 2023 ($828.5 Mil) to Sep. 2023 ($808.9 Mil) but then
increased
from Sep. 2023 ($808.9 Mil) to Dec. 2023 ($1,021.8 Mil).
ADMA Biologics's annual market cap
increased
from Dec. 2021 ($276.1 Mil) to Dec. 2022 ($860.6 Mil) and
increased
from Dec. 2022 ($860.6 Mil) to Dec. 2023 ($1,021.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ADMA Biologics's Enterprise Value for Today is $1,615.1 Mil.
ADMA Biologics Market Cap Historical Data
The historical data trend for ADMA Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ADMA Biologics's Market Cap
For the Biotechnology subindustry, ADMA Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Market Cap falls into.
ADMA Biologics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ADMA Biologics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (NAS:ADMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ADMA Biologics Market Cap Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 